UC San Diego researchers discovered that patient survival from sepsis is associated with higher platelet counts, and identified two currently available drugs that protect these blood cells and improve survival in mice with sepsis.
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
UC San Diego School of Medicine researchers identified chemical compounds that prevent stress-induced clumping of TDP-43 protein in ALS motor neurons grown in the lab — a starting point for new ALS therapeutics.
Researchers at UC San Diego School of Medicine generated a new mouse model that mimics human acne for the first time, and used it to validate the concept of “good” and “bad” acne bacteria and introduce new possibilities for targeted treatments and vaccines.
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
